Company overview
Advancing Cell-Based Innovation for a Healthier Future.
JY BioMed is a biotechnology company dedicated to advancing the next generation of cell and exosome therapies for cancer, regenerative medicine, and immune modulation. Headquartered in Taipei, Taiwan, we combine translational research, scalable manufacturing, and early clinical development to drive innovation in healthcare. Our pipeline spans gamma delta T cell therapies, natural killer (NK) cell therapies, mesenchymal stem cell (MSC) and exosome platforms, dendritic cell immunotherapies, and CEACAM6-targeting antibody-drug conjugates (ADCs). While most of our programs remain in preclinical stages, our umbilical cord-derived MSC platform has successfully progressed into a Phase 1 clinical trial in Taiwan, marking a key milestone in our translational journey.
Through collaborations with leading academic institutions, clinical centers, and industry partners, JY BioMed is building a robust foundation for the future application of cell-based therapeutics in areas of high unmet medical need.
Regulatory Disclaimer
JY BioMed’s therapies and technologies are at various stages of development. Except for the UC-MSC platform currently under Phase 1 clinical evaluation in Taiwan, all other programs remain in preclinical investigation and have not been approved for clinical or commercial use by any regulatory authority.
